Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Sells $5,763,494.90 in Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Robert Desantis sold 11,545 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $499.22, for a total transaction of $5,763,494.90. Following the completion of the sale, the executive vice president now directly owns 5,224 shares of the company’s stock, valued at approximately $2,607,925.28. This trade represents a 68.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Intuitive Surgical Price Performance

Intuitive Surgical stock traded up $9.07 during mid-day trading on Friday, reaching $485.85. The company had a trading volume of 1,418,428 shares, compared to its average volume of 1,433,294. Intuitive Surgical, Inc. has a 1 year low of $364.17 and a 1 year high of $616.00. The company has a market capitalization of $173.05 billion, a P/E ratio of 75.72, a P/E/G ratio of 5.85 and a beta of 1.43. The stock’s 50-day simple moving average is $568.47 and its 200-day simple moving average is $531.22.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. M.E. Allison & CO. Inc. purchased a new position in Intuitive Surgical in the fourth quarter valued at about $449,000. Seilern Investment Management Ltd purchased a new position in shares of Intuitive Surgical during the 4th quarter worth approximately $82,517,000. Sycomore Asset Management increased its stake in shares of Intuitive Surgical by 27.4% during the 4th quarter. Sycomore Asset Management now owns 18,945 shares of the medical equipment provider’s stock worth $9,214,000 after purchasing an additional 4,079 shares in the last quarter. Exome Asset Management LLC increased its stake in shares of Intuitive Surgical by 16.8% during the 3rd quarter. Exome Asset Management LLC now owns 7,427 shares of the medical equipment provider’s stock worth $3,649,000 after purchasing an additional 1,069 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Intuitive Surgical by 5.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,843 shares of the medical equipment provider’s stock worth $5,138,000 after purchasing an additional 525 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on ISRG. Raymond James boosted their price target on shares of Intuitive Surgical from $560.00 to $688.00 and gave the company an “outperform” rating in a research report on Friday, January 24th. Evercore ISI upped their target price on shares of Intuitive Surgical from $490.00 to $530.00 in a report on Monday, January 27th. Barclays upped their target price on shares of Intuitive Surgical from $610.00 to $674.00 in a report on Monday, January 27th. Jefferies Financial Group upped their target price on shares of Intuitive Surgical from $475.00 to $575.00 in a report on Monday, January 27th. Finally, Bernstein Bank upped their target price on shares of Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus price target of $613.10.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.